Related Experiment Video
Updated: Jul 9, 2026
Development of a Murine Model for Femoral Artery Anastomotic Stenosis
Published on: April 18, 2025
Risk factors for persistent ductus arteriosus patency during indomethacin treatment
Nancy Chorne1, Priya Jegatheesan, Emil Lin
1Cardiovascular Research Institute and Department of Pediatrics, University of California, San Francisco, California, USA.
Insights
Patent ductus arteriosus closure can be influenced by factors beyond prostaglandin production, even with indomethacin treatment. Immature gestational age, lack of antenatal steroids, respiratory distress, and race are key independent risk factors.
Area of Science:
- Neonatal Medicine
- Cardiovascular Physiology
- Pharmacology
Background:
- Patent ductus arteriosus (PDA) is a common condition in preterm infants.
- Prostaglandin inhibition, using drugs like indomethacin, is a standard treatment for PDA.
- Some cases of PDA persist despite prostaglandin inhibition, suggesting alternative regulatory mechanisms.
Purpose of the Study:
- To investigate factors influencing PDA closure independent of prostaglandin production.
- To test the hypothesis that non-prostaglandin pathways regulate PDA persistence.
Main Methods:
- A cohort of 446 infants treated with indomethacin within 15 hours of birth was analyzed.
- Multiple logistic regression modeling identified variables associated with persistent ductus patency.
Main Results:
- Immature gestational age was significantly associated with PDA persistence.
- Lack of antenatal betamethasone exposure correlated with persistent ductus patency.
- Severity of respiratory distress and Caucasian race were also independent risk factors for PDA persistence.
Conclusions:
- Gestational age, antenatal glucocorticoid exposure, respiratory distress, and race are independent risk factors for PDA closure.
- These factors may influence PDA treatment outcomes even when prostaglandin production is inhibited.
- Further research into these risk factors could reveal novel therapeutic targets for PDA.
Objective:
To test the hypothesis that patent ductus arteriosus that fail to close with prostaglandin inhibition may be regulated by mechanisms that act independently of prostaglandin production.
Study Design:
We examined a cohort of 446 infants who were treated with indomethacin (within 15 hours of birth) to inhibit prostaglandin production. We used multiple logistic regression modeling to determine which perinatal/neonatal variables were most closely associated with the persistence of ductus patency in the presence of diminished prostaglandin production.
Results:
We identified 4 variables (immature gestational age, lack of exposure to antenatal betamethasone, severity of respiratory distress, and Caucasian race) that were significantly and independently associated with the degree of ductus patency.
Conclusion:
Gestational age, antenatal glucocorticoid exposure, respiratory distress, and race are independent risk factors that appear to affect ductus closure even when indomethacin has been used to inhibit prostaglandin production. Future studies of these risk factors may identify new potential targets for patent ductus arteriosus treatment.
